HDAC inhibitors differ in their ability to suppress individual anti-apoptotic proteins—for example suberanilohydroxamic acid (SAHA/Vorinostat) suppressed Bcl-XL levels in melanoma cells while valproic acid (VPA) did not [94]. The gene discussed is BCL2L1; the disease is melanoma.